Comment from Altis Labs, Inc.

Summary: Altis Labs, an oncology-focused computational imaging company, supports the pilot program and provides specific recommendations on trial types, therapeutic focus, and evaluation metrics. They argue that the pilot should prioritize Phase Ib/2 solid tumor trials to demonstrate how AI-derived efficacy endpoints can accelerate go/no-go decisions and improve drug development efficiency.